Tesamorelin and Ipamorelin Study Findings - Biotech Peptides

Tesamorelin and Ipamorelin Study Findings

by Dr. Usman | Mar 9, 2022 | Research

Tesamorelin, also known as TH9507, is a synthetic growth hormone-releasing factor agonist that may stimulate the production and release of endogenous growth hormone. It is comprised of all 44 amino acids of GHRH with a trans3-hexenoic acid group. Additionally, it is speculated to be more robust and stable than GHRH and may be resistant to cleavage by the dipeptidyl aminopeptidase enzyme. Tesamorelin is believed to activate the GHRH receptor in the pituitary gland, causing the synthesis and release of growth hormone-releasing hormone. This hormone, in turn, is speculated to act on several cells, including hepatocytes, to stimulate the production of insulin-like growth factor 1 (IGF-1). IGF-1 is considered to mediate many of the effects of growth hormones, including liver growth, suppression of programmed cell death, impaired glucose tolerance, and lipolysis.

Ipamorelin is a synthetic pentapeptide with distinct and specific growth hormone (GH) release properties, potentially as impactful as researchers suggest GHRP-6 is. It is believed to stimulate GH release via GHRP-like receptors, and surprisingly, it may not release ACTH or cortisol at levels significantly different from those observed after GHRH stimulation. This action is speculated to make ipamorelin potentially the first GHRH agonist specific for GH release, similar to GHRH. Ipamorelin appears to work in a completely different way to stimulate the release of growth hormones. It is suggested to bind to ghrelin receptors in the pituitary gland without affecting other hormones in the body. Ghrelin, which it interacts with, is believed to have profound metabolic regulatory effects, including increased or decreased hunger, suppression of the breakdown of accumulated fat, and most importantly, the release of growth hormone from the pituitary gland.

Dr. Usman

Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.

Latest Post

BPC157: Molecular Characterization, Pleiotropic Signaling Mechanisms, and Preclinical Research

Copper Peptides: Molecular Characterization, Mechanistic Biology, and Emerging Research

Modified GRF 1-29 and GHRP-2 Peptide Blend: Receptor Pharmacology, Somatotroph Signaling, and Neuroendocrine Research

Fragment 176-191, Modified GRF 1-29, and Ipamorelin Blend: Adipose Metabolism, GH Axis Modulation, and Receptor Signaling Research

PNC-27: Structural Characterization, HDM-2-Dependent Membrane Targeting, and Selective Tumor Cell Necrosis